{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T13:42:17Z","timestamp":1777642937809,"version":"3.51.4"},"reference-count":17,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T00:00:00Z","timestamp":1530144000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This is a phase II study of panobinostat, an oral pan\u2010HDAC inhibitor, combined with rituximab in patients with relapsed diffuse large B cell lymphoma. Panobinostat was administered orally 3 times a week every other week on a 28\u2010day cycle. Rituximab was administered weekly during the first cycle, then on Day 1 of cycles 2 to 6. Patients without disease progression after 6 cycles continued panobinostat monotherapy for up to 6 additional cycles in the absence of disease progression. Eighteen eligible subjects were enrolled, and 18 were evaluable for response. The overall response rate was 11% (90% CI [2%\u201034%]) with 2 subjects having a partial response. The duration of response in these subjects was 51 and 60\u00a0days. Five additional subjects had stable disease with 3 subjects having tumor reduction between 27 and 44%, not meeting criteria for partial response. One subject with stable disease remained on therapy a total of 12 cycles. The most common toxicities while on study were thrombocytopenia (14 patients, 78%); fatigue (11, 61%); anemia (10, 56%); diarrhea (8, 44%); and nausea, lymphopenia, anorexia, and hypophosphatemia (5 each, 28% of patients), the majority of which was grade 2 or less. These data indicate that the combination of panobinostat with rituximab is able to induce responses in a limited number of subjects with relapsed diffuse large B cell lymphoma.<\/jats:p>","DOI":"10.1002\/hon.2515","type":"journal-article","created":{"date-parts":[[2018,6,29]],"date-time":"2018-06-29T06:54:28Z","timestamp":1530255268000},"page":"633-637","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Panobinostat in combination with rituximab in heavily pretreated diffuse large B\u2010cell lymphoma: Results of a phase II study"],"prefix":"10.1002","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4867-1909","authenticated-orcid":false,"given":"Jeffrey A.","family":"Barnes","sequence":"first","affiliation":[{"name":"Massachusetts General Hospital Cancer Center Dana\u2010Farber Cancer Institute  Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Redd","sequence":"additional","affiliation":[{"name":"Dana\u2010Farber Cancer Institute  Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David C.","family":"Fisher","sequence":"additional","affiliation":[{"name":"Dana\u2010Farber Cancer Institute  Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ephraim P.","family":"Hochberg","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center Dana\u2010Farber Cancer Institute  Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tak","family":"Takvorian","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center Dana\u2010Farber Cancer Institute  Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna","family":"Neuberg","sequence":"additional","affiliation":[{"name":"Dana\u2010Farber Cancer Institute  Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Jacobsen","sequence":"additional","affiliation":[{"name":"Dana\u2010Farber Cancer Institute  Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy S.","family":"Abramson","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center Dana\u2010Farber Cancer Institute  Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,6,28]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-11-3911"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/07357900600814490"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.5957"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.6.1169"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1618"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428190109097730"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng1018"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70440-1"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.38"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.1350"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90015-9"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07484.x"},{"issue":"21","key":"e_1_2_7_15_1","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1182\/blood.V124.21.1755.1755","article-title":"Panobinostat as salvage treatment for patients with relapsed\/refractory diffuse large B\u2010cell lymphoma not eligible to high dose therapy: a phase II study of the Fondazione Italiana Linfomi (FIL)","volume":"124","author":"Zaja F","year":"2014","journal-title":"Blood"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-02-699520"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-220889"},{"issue":"21","key":"e_1_2_7_18_1","first-page":"18","article-title":"Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B\u2010cell lymphoma. ASH annual meeting abstracts","volume":"118","author":"Barnes JA","year":"1635","journal-title":"2011 November"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.2515","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2515","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T13:59:47Z","timestamp":1694872787000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,28]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.1002\/hon.2515"],"URL":"https:\/\/doi.org\/10.1002\/hon.2515","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,28]]},"assertion":[{"value":"2018-04-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}